Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.58 | N/A | +1.54% |
management commentary, guidance changes, and full analysis available with Pro.
| +1.54% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings performance, highlighting their commitment to innovation. They emphasized the importance of adapting to market demands.
We are pleased with our performance this quarter.
Our focus remains on innovation and meeting consumer needs.
This earnings report shows that Johnson & Johnson exceeded expectations on EPS, which is a positive sign for the company. However, the lack of revenue data and guidance may leave investors cautious. The stock reaction is not available, indicating uncertainty in market response.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BROWN & BROWN INC
Jan 23, 2017